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experiences, three randomized-con-
trolled trials (ROSEL, STAR, RTOG 
1021) have been started, all comparing 
SBRT with surgery, either lobectomy or 
sublobar resection. However, all three 
trials closed early because of very poor 
accrual of patients. Was all the effort 
of these randomized trials for nothing? 
Certainly no! From a technical perspec-
tive, these trials achieved highly valu-
able standardization, quality-assurance, 
and credentialing procedures for imple-
mentation and practice of SBRT.7,8 
From a clinical perspective, these tri-
als engaged multidisciplinary discus-
sion and interaction aiming at the best 
treatment approach for each individual 
patient.
Propensity-score matching is 
a statistical tool, which attempts to 
account for confounding covariates 
and thereby simulates a randomized 
trial based on retrospectively acquired 
data. Several such comparisons have 
been performed and all concluded that 
SBRT is at least as effective as sublobar 
resection and comparable with lobec-
tomy.4,9–11 This conclusion seems robust 
with reproducible results in these differ-
ent studies. Nevertheless, only known 
and available confounding covariates 
were statistically corrected, which 
leaves uncertainties behind.
How to proceed now that 
 level-one evidence will not be available 
for comparison of SBRT and surgical 
resection? In daily clinical practice, 
patients should not only be discussed 
but be informed by a multidisciplinary 
team about the available (or lack of) evi-
dence, the surgical and SBRT options, 
and their specific pros and cons. This 
is especially true for the elderly and 
comorbid patient population as stated 
by Dr. Barlett but the encouraging 
outcome of SBRT might increase the 
number of younger and fitter patients 
actively refusing surgery and opting 
for SBRT: we should prepare ourselves 
with the establishment of prospective 
databases for future generation of the 
highest data quality and evidence possi-
ble in the absence of randomized trials.
Matthias Guckenberger, MD
Department of Radiation Oncology
University of Würzburg
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To the Editor:
In their report, Sholl et al.1 elegantly 
demonstrate strong association between 
anaplastic lymphoma kinase immunohis-
tochemistry (ALK IHC) and ALK fluo-
rescence in situ hybridization (FISH) for 
detecting ALK rearrangements in lung 
adenocarcinoma. Using the clone 5A4 
the authors observed that ALK IHC was 
93% sensitive and 100% specific when 
compared with ALK FISH. We agree with 
their conclusion that a combined FISH 
and IHC approach enhances chances to 
identify ALK rearrangements in non–
small-cell lung cancer.
However, we would like to com-
ment on their interpretation of a FISH 
result considered as false positive.
In case 2, ALK FISH reveals tumor 
nuclei showing multiple fused signals (>2) 
associated with a single green signal (Fig. 
2).1 The authors interpret this profile as an 
atypical ALK rearrangement, arguing for 
an asymmetric splitting of the green probe 
(5′ centromeric) consisting of a single 
 bright-green signal in addition to a small 
green signal fused to a red signal.
But the ALK breakpoint is known to 
be constant.2 This molecular feature justi-
fies the use of the Vysis ALK Break Apart 
FISH Probe Kit with a green probe (5’ 
centromeric) and a red probe (3′ telomeric, 
complementary to the ALK tyrosine kinase 
domain) surrounding the ALK breakpoint. 
ALK rearrangement leads to an increased 
distance between the green signal (5′) 
and the red signal (3′). Single red signals 
(3′), without corresponding green signals, 
because of a deletion of 5′ end of ALK, 
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(such as clinical factors, pathologic 
features, and tumor markers).
Second, in the study by Hata 
et al.4 two patients had a point muta-
tion in exon 18 (G719X). To date, no 
final conclusion has been reached on 
the prognostic role of mutation type 
in EGFR-TKIs treatment. Several pre-
vious phase III studies only enrolled 
the patients with common EGFR 
mutations (L858R and exon 19 dele-
tions).1–3 In contrast, in the LUX-Lung 
3 study,5 L858R and exon 19 dele-
tions were defined as common EGFR 
mutations and others were defined as 
uncommon mutations. Interestingly, 
in common EGFR mutations (L858R 
and exon 19 deletions), median PFS 
was 13.6 months for afatinib (hazard 
ratio [HR], 0.47; 95% CI, 0.34–0.65; 
p=0.001) but in unselected EGFR 
mutations, median PFS was 11.1 
months for afatinib (HR, 0.58; 95% 
CI, 0.43–0.78; P=0.001). We specu-
late that the efficacy of EGFR-TKIs 
in common EGFR mutations is supe-
rior to that in uncommon mutations 
(although the numbers of uncommon 
mutations were very small in the LUX-
Lung 3 study, 26 in afatinib arm and 
11 in chemotherapy arm). However, 
Hata et al. did not mention whether 
or not the survival analysis of their 
study4 included these two patients, and 
if included, this may affect the results.
Fei Zhou, MD
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epidermal growth factor receptor–tyro-
sine kinase inhibitors (EGFR-TKI) in 
personalized first-line treatment in non–
small-cell lung cancer patients harboring 
EGFR-sensitive mutations. However, in 
the West Japan Thoracic Oncology Group 
(WJTOG) 3405, European Tarceva ver-
sus Chemotherapy (EURTAC), and 
OPTIMAL studies, there were only one, 
one, and eight patients with squamous 
cell carcinoma (SQC) in each cohort, 
respectively.1–3 Thus, the efficacy of 
EGFR-TKIs for EGFR-mutated SQC 
needs to be further established.
In this context, we read the 
article by Hata and colleagues4 with 
great interest. We were attracted by the 
results, particularly regarding the effi-
cacy of EGFR-TKIs in EGFR-mutated 
SQC patients. However, to better under-
stand these conclusions, we believe 
some other considerations should be 
taken into account.
First, in the study by Hata et al.,4 
the median progression-free sur-
vival (PFS) (EGFR-positive versus 
 -negative) was 1.4 months (95% con-
fidence interval [CI], 0.7–5.8 months) 
versus 1.8 months (95% CI, 1.0–2.4 
months, p=0.1734) and the median 
overall survival (EGFR-positive ver-
sus -negative) was 14.6 months (95% 
CI, 2.9–undeterminable months) ver-
sus 11.0 months (95% CI, 5.7–15.7 
months, p=0.5472), respectively. 
Hence Hata et al. indicated that EGFR-
TKIs seem to be generally less effective 
in EGFR-mutated SQC than in EGFR-
mutated adenocarcinoma. However, it 
should be noted that previous clinical 
trials compared the efficacy of first-
line EGFR-TKIs versus the standard 
chemotherapy regimens in EGFR-
mutated patients,1–3 thus, we consider 
that the efficacy of chemotherapy in 
EGFR-mutated SQC patients is also 
very important (there were 14 EGFR-
mutated SQC patients receiving plati-
num doublets as first-line treatment in 
their study,4 however, the authors did 
not present the efficacy information). 
Moreover, we believe that when there 
is strong evidence to demonstrate that 
EGFR-TKIs are significantly superior 
to chemotherapy in EGFR-mutated 
SQC patients, the identification of 
SQC patients by using EGFR muta-
tion analysis will be more meaningful 
How Sensitive 
Are Epidermal 
Growth Factor 
Receptor–Tyrosine 
Kinase Inhibitors 
for Squamous Cell 
Carcinoma of the Lung 
Harboring EGFR Gene–
Sensitive Mutations?
are also positive and are associated with a 
positive response to  crizotinib treatment.3
In contrast, single green signals 
(5′) are not considered ALK FISH posi-
tive because it lacks ALK tyrosine kinase 
domain. It is likely that the reported case 
(case 2) corresponds to this situation 
rather than an asymmetric splitting of 
the 5′ probe. We have already seen simi-
lar cases in our practice and it does not 
surprise us that crizotinib therapy failed.
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To the Editor:
Several randomized phase III clini-
cal trials have revealed the pivotal role of 
